Target validation and structure-based virtual screening to Discover potential lead molecules against the oncogenic NSD1 histone methyltransferase
The aim of the study was to validate Nuclear receptor-binding SET Domain NSD1 as a cancer drug target followed by the design of lead molecules against NSD1. TCGA clinical data, molecular expression techniques were used to validate the target and structure-based virtual screening was performed to design hits against NSD1. Clinical data analysis suggests the role of NSD1 in metastasis, prognosis and influence on overall survival in various malignancies. Furthermore, the mRNA and protein expression profile of NSD1 was evaluated in various cell lines. NSD1 was exploited as a target protein for in silico design of inhibitors using two major databases including ZINC15 and ChemDiv by structure-based virtual screening approach. Virtual screening was performed using the pharmacophore hypothesis designed with a protein complex S-adenosyl-l-methionine (SAM) as an endogenous ligand. Subsequently, a combined score was used to distinguish the top 10 compounds from the docking screened compounds having high performance in all four scores (docking score, XP, Gscore, PhaseScreenScore, and MMGBSA delta G Bind). Finally, the top three Zinc compounds were subjected to molecular dynamic simulation. The binding MMGBSA data suggests that ZINC000257261703 and ZINC000012405780 can be taken for in vitro and in vivo studies as they have lesser MMGBSA energy towards the cofactor binding site of NSD1 than the sinefungin. Our data validates NSD1 as a cancer drug target and provides promising structures that can be utilized for further lead optimization and rational drug design to open new gateways in the field of cancer therapeutics. Graphical abstract.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:11 |
|---|---|
| Enthalten in: |
In Silico Pharmacology - 11(2023), 1 vom: 11. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Bhat, Zahid Rafiq [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Cancer |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. |
|---|
| doi: |
10.1007/s40203-023-00158-0 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR052721299 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR052721299 | ||
| 003 | DE-627 | ||
| 005 | 20230812064858.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230812s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40203-023-00158-0 |2 doi | |
| 035 | |a (DE-627)SPR052721299 | ||
| 035 | |a (SPR)s40203-023-00158-0-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Bhat, Zahid Rafiq |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Target validation and structure-based virtual screening to Discover potential lead molecules against the oncogenic NSD1 histone methyltransferase |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. | ||
| 520 | |a The aim of the study was to validate Nuclear receptor-binding SET Domain NSD1 as a cancer drug target followed by the design of lead molecules against NSD1. TCGA clinical data, molecular expression techniques were used to validate the target and structure-based virtual screening was performed to design hits against NSD1. Clinical data analysis suggests the role of NSD1 in metastasis, prognosis and influence on overall survival in various malignancies. Furthermore, the mRNA and protein expression profile of NSD1 was evaluated in various cell lines. NSD1 was exploited as a target protein for in silico design of inhibitors using two major databases including ZINC15 and ChemDiv by structure-based virtual screening approach. Virtual screening was performed using the pharmacophore hypothesis designed with a protein complex S-adenosyl-l-methionine (SAM) as an endogenous ligand. Subsequently, a combined score was used to distinguish the top 10 compounds from the docking screened compounds having high performance in all four scores (docking score, XP, Gscore, PhaseScreenScore, and MMGBSA delta G Bind). Finally, the top three Zinc compounds were subjected to molecular dynamic simulation. The binding MMGBSA data suggests that ZINC000257261703 and ZINC000012405780 can be taken for in vitro and in vivo studies as they have lesser MMGBSA energy towards the cofactor binding site of NSD1 than the sinefungin. Our data validates NSD1 as a cancer drug target and provides promising structures that can be utilized for further lead optimization and rational drug design to open new gateways in the field of cancer therapeutics. Graphical abstract | ||
| 650 | 4 | |a NSDs |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a NSD1 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Histone lysine methyl transferases |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a cancer |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a TCGA |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Virtual screening |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Gahlawat, Anuj |4 aut | |
| 700 | 1 | |a Kumar, Navneet |4 aut | |
| 700 | 1 | |a Sharma, Nisha |4 aut | |
| 700 | 1 | |a Garg, Prabha |4 aut | |
| 700 | 1 | |a Tikoo, Kulbhushan |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t In Silico Pharmacology |d Berlin : SpringerOpen, 2013 |g 11(2023), 1 vom: 11. Aug. |w (DE-627)SPR032902050 |w (DE-600)2702993-1 |x 2193-9616 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2023 |g number:1 |g day:11 |g month:08 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40203-023-00158-0 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2023 |e 1 |b 11 |c 08 | ||